Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins. The high rate of synthesis makes myeloma cells dependent on protein processing mechanisms related to the...
Saved in:
Main Authors: | Marta Pelon (Author), Patryk Krzeminski (Author), Zuzanna Tracz-Gaszewska (Author), Irena Misiewicz-Krzeminska (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014) -
Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
by: Yuan Peng, et al.
Published: (2024) -
Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
by: Maiko Matsushita, et al.
Published: (2023) -
Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate
by: Daniela Brünnert, et al.
Published: (2023) -
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes
by: Patrizia Leone, et al.
Published: (2024)